|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | I-Flow Corp. (NASDAQ: IFLO), a manufacturer of pain management and infusion therapy drug delivery systems. |
|---|---|
| Transferring Party | AcryMed Inc., a privately-owned developer of infection control and wound healing products. |
| Sector | Medical Devices |
| Date | December 14, 2007 |
| Analysis AcryMed has patented technology in the woundcare area, developed the proprietary nanoparticle treatment process for the silver coating on I-Flow's ON-Q SilverSoaker™ Catheters, and treated these catheters since 05. In addition to those inherent synergies, the deal expands I-Flow's strategic focus to include general surgical site care management, wound care and infection control, in addition to regional anesthesia for post-surgical pain management. Deal value $25m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |